文献速递眼底病与葡萄膜炎青光眼

玻璃体内抗VEGF注射降低新生血管性年龄相关性黄斑变性患者的房水流出易度

Intravitreal Anti-VEGF Injections Reduce Aqueous Outflow Facility in Patients With Neovascular Age-Related Macular Degeneration.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2017-01-01

本研究纳入接受单侧玻璃体内抗VEGF注射的年龄相关性黄斑变性患者,分为≤10次和≥20次注射两组,测量注射眼与未注射对侧眼的眼压和眼压描记流出易度。结果显示,≥20次注射组注射眼流出易度较对侧未注射眼降低12%(P=0.02),≤10次注射组无降低(P=0.4);未注射眼眼压>21 mmHg者注射眼流出易度平均降低46%(P=0.01)。结论认为长期抗VEGF注射显著降低流出易度,基线眼压偏高者降低最明显。

要点

  • ≥20次抗VEGF注射眼流出易度较对侧未注射眼降低12%(P=0.02),≤10次组无降低(P=0.4)。
  • 未注射眼眼压>21 mmHg者注射眼流出易度平均降低46%(P=0.01),降幅显著大于未注射眼眼压≤21 mmHg者(P=2×10-4)。
  • 注射眼眼压>21 mmHg者双眼间流出易度与眼压差异显著大于注射眼眼压≤21 mmHg者(P=2×10-4和P=7×10-4)。

核心结论

  • 长期抗VEGF注射显著降低年龄相关性黄斑变性患者的房水流出易度,基线眼压偏高者降低最明显。
  • 作者认为,实施抗VEGF注射的眼科医生应了解这些发现,并密切监测患者眼压变化或青光眼证据,尤其是已有眼压偏高者。

研究设计与样本

  • 招募接受单侧玻璃体内抗VEGF注射的年龄相关性黄斑变性患者,分为总注射次数≤10次组和≥20次组。
  • 测量并比较注射眼与未注射对侧眼的眼压和眼压描记流出易度,并评估流出易度降低的危险因素。

主要发现

  • ≥20次注射组注射眼流出易度较对侧未注射眼降低12%(P=0.02)。
  • ≤10次注射组未见流出易度降低(P=0.4)。
  • 未注射眼眼压>21 mmHg者(n=5)注射眼流出易度平均较未注射对侧眼降低46%(P=0.01),降幅显著大于未注射眼眼压≤21 mmHg者(P=2×10-4)。
  • 注射眼眼压>21 mmHg者(n=6)双眼间流出易度与眼压差异显著大于注射眼眼压≤21 mmHg者(P=2×10-4和P=7×10-4)。

关键数值与推荐

  • ≥20次注射组注射眼流出易度较对侧未注射眼降低12%(P=0.02)。
  • ≤10次注射组流出易度无降低(P=0.4)。
  • 未注射眼眼压>21 mmHg者(n=5)注射眼流出易度平均降低46%(P=0.01),与未注射眼眼压≤21 mmHg者的差异P=2×10-4。
  • 注射眼眼压>21 mmHg者(n=6)双眼间流出易度差异P=2×10-4、眼压差异P=7×10-4。

临床怎么用

  • 作者认为,实施抗VEGF注射的眼科医生应了解这些发现,并密切监测患者眼压变化或青光眼证据,尤其是已有眼压偏高者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We assess the effect of intravitreal anti-VEGF injections on tonographic outflow facility. METHODS: Patients with age-related macular degeneration who had received unilateral intravitreal anti-VEGF injections were recruited into two groups, those with ≤10 and those with ≥20 total anti-VEGF injections. Intraocular pressure and tonographic outflow facility of injected and uninjected fellow eyes were measured and compared between groups. Risk factors for development of reduced outflow facility also were assessed. RESULTS: Outflow facility was 12% lower in the injected eyes of patients who received ≥20 anti-VEGF injections, compared to contralateral uninjected eyes (P = 0.02). In contrast, there was no facility reduction for patients with ≤10 anti-VEGF injections (P = 0.4). In patients with ocular hypertension in the uninjected eye (IOP > 21 mm Hg, n = 5), the outflow facility of injected eyes was on average 46% lower (P = 0.01) than in the uninjected fellow eyes. This was significantly greater than the difference observed in patients with IOP ≤ 21 mm Hg in the uninjected eye (P = 2 × 10-4). In patients with ocular hypertension in the injected eye (n = 6) the differences in facility and IOP between contralateral eyes were significantly greater than in patients with IOP ≤ 21 mm Hg in the injected eye (P = 2 × 10-4 and P = 7 × 10-4, respectively). CONCLUSIONS: Chronic anti-VEGF injections significantly reduce outflow facility in patients with AMD. The greatest facility reduction is observed in patients with baseline ocular hypertension. Ophthalmologists who administer anti-VEGF injections should be aware of these findings and monitor patients closely for changes in IOP or evidence of glaucoma, especially in those with pre-existing ocular hypertension.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Wen JC, Reina-Torres E, Sherwood JM, et al. Intravitreal Anti-VEGF Injections Reduce Aqueous Outflow Facility in Patients With Neovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2017. PMID: 28358961. doi:10.1167/iovs.16-20786

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。